Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | BCAT1 | P54687 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13271499 | 0.79 | ALOX15 (0.56) | PYGLMAPTKDM4EALOX15F10 | |
| SCHEMBL12879208 | 0.79 | ALDH1A1 (0.45) | PYGLKDM4EMEN1NPC1RAB9A | |
| SCHEMBL1205179 | 0.79 | KMT2A (0.46) | PYGLF10KMT2A | |
| SCHEMBL12879180 | 0.79 | ALDH1A1 (0.45) | PYGLKDM4EMEN1NPC1RAB9A | |
| SCHEMBL1205177 | 0.79 | KMT2A (0.46) | PYGLF10KMT2A | |
| SCHEMBL4938802 | 0.79 | F7 (0.55) | PYGLBCAT1MEN1KMT2A | |
| SCHEMBL25758892 | 0.78 | ALOX15 (0.59) | PYGLMAPTKDM4EALOX15RET | |
| SCHEMBL1202368 | 0.78 | MAPT (0.47) | PYGLMAPTKDM4EBCAT1GAA | |
| SCHEMBL12879173 | 0.78 | PYGL (0.53) | PYGLMAPTKDM4EBCAT1MEN1 | |
| SCHEMBL1202468 | 0.77 | ATM (0.52) | PYGLMAPTKDM4EBCAT1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884112-B2 | Glycogen phosphorylase inhibitor; antidiabetic agents; hypoglycemic agents; hypercholesterolemia; hypotensive agents; antilipemic agents; hypotensive agents; antiischemic agents | BRADLEY STUART EDWARD | 2011-02-08 | — | — | US | disclosed |
| US-7884112-B2 | Glycogen phosphorylase inhibitor; antidiabetic agents; hypoglycemic agents; hypercholesterolemia; hypotensive agents; antilipemic agents; hypotensive agents; antiischemic agents | BRADLEY STUART EDWARD | 2011-02-08 | — | — | US | disclosed |
| US-7884112-B2 | Glycogen phosphorylase inhibitor; antidiabetic agents; hypoglycemic agents; hypercholesterolemia; hypotensive agents; antilipemic agents; hypotensive agents; antiischemic agents | BRADLEY STUART EDWARD | 2011-02-08 | — | — | US | disclosed |
| EP-1725555-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PROSIDION LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| EP-1725555-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PROSIDION LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | BRADLEY STUART EDWARD | 2008-10-30 | — | — | US | disclosed |
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | BRADLEY STUART EDWARD | 2008-10-30 | — | — | US | disclosed |
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | BRADLEY STUART EDWARD | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | PYGL, PDK1, PYGM | PYGL 1/4885MAPT 3077/4885LEF1 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.